This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VBI Vaccines Dirección

Dirección controles de criterios 3/4

El CEO de VBI Vaccines es Jeff Baxter , nombrado en May 2016, tiene una permanencia de 8.25 años. compensación anual total es $893.55K, compuesta por 78.1% salario y 21.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.071% de las acciones de la empresa, por valor de €400.86. La antigüedad media del equipo directivo y de la junta directiva es de 6.9 años y 6.6 años, respectivamente.

Información clave

Jeff Baxter

Chief Executive Officer (CEO)

US$893.5k

Compensación total

Porcentaje del salario del CEO	78.1%
Permanencia del CEO	8.3yrs
Participación del CEO	0.07%
Permanencia media de la dirección	6.9yrs
Promedio de permanencia en la Junta Directiva	6.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jeff Baxter en comparación con los beneficios de VBI Vaccines?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$894k	US$698k	-US$94m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$120m
Dec 31 2022	US$2m	US$678k	-US$113m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$605k	-US$70m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$2m	US$535k	-US$46m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$1m	US$500k	-US$55m
Sep 30 2019	n/a	n/a	-US$63m
Jun 30 2019	n/a	n/a	-US$62m
Mar 31 2019	n/a	n/a	-US$66m
Dec 31 2018	US$1m	US$465k	-US$64m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$826k	US$450k	-US$39m

Compensación vs. Mercado: La compensación total de Jeff($USD893.55K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD483.75K).

Compensación vs. Ingresos: La compensación de Jeff ha sido consistente con los resultados de la empresa en el último año.

CEO

Jeff Baxter (63 yo)

8.3yrs

Permanencia

US$893,547

Compensación

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% € 400.9
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	sin datos	0.0079% € 44.9
David Anderson	Chief Scientific Officer	8.3yrs	US$564.56k	0.017% € 97.7
Francisco Diaz-Mitoma	Chief Medical Officer	8.5yrs	US$549.22k	0.049% € 277.0
Nicole Anderson	Director of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Athena Kartsaklis	Senior VP of Finance	6.9yrs	sin datos	sin datos
Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	7.3yrs	sin datos	0.025% € 139.7
Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	4.6yrs	sin datos	sin datos
T. Buckley	Senior Vice President of Business Development	4.6yrs	sin datos	sin datos
John Dillman	Chief Commercial Officer	2.1yrs	sin datos	sin datos

6.9yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LO9A es experimentado (6.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% € 400.9
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	sin datos	0.0079% € 44.9
Steven S. Gillis	Independent Chairperson of the Board	8.3yrs	US$194.03k	0.0098% € 55.6
Denis Burger	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Patriarca	Member of Scientific Advisory Board	6.6yrs	sin datos	sin datos
Stanley Plotkin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Damian Braga	Chairperson of the Commercial Advisory Board & Independent Director	4.4yrs	US$105.18k	0% € 0
Michel De Wilde	Independent Director and Chair of Scientific & Clinical Advisory Board	8.3yrs	US$107.68k	0.0058% € 33.0
Blaine McKee	Independent Director	5.6yrs	US$120.18k	0% € 0
Joanne Cordeiro	Independent Director	5.3yrs	US$127.68k	0% € 0
Robert Pass	Member of Scientific Advisory Board	6.6yrs	sin datos	sin datos
Adam Finn	Member of Scientific Advisory Board	6.6yrs	sin datos	sin datos

6.6yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de LO9A se considera experimentada (6.6 años de antigüedad promedio).

This company listing is no longer active

VBI Vaccines Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

VBI Vaccines Inc., Annual General Meeting, Jun 25, 2024

Insufficient new directors

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

Recent updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc., Annual General Meeting, Jun 25, 2024

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Second quarter 2023 earnings released: US$5.18 loss per share (vs US$5.31 loss in 2Q 2022)

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

Now 20% undervalued after recent price drop

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: US$3.22 loss per share (vs US$2.47 loss in 1Q 2022)

Insufficient new directors

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.068 loss in 2Q 2021)

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

First quarter 2022 earnings released: US$0.082 loss per share (vs US$0.07 loss in 1Q 2021)

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

No longer forecast to breakeven

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

VBI Vaccines Inc. Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients

Forecast to breakeven in 2024

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

VBI Vaccines Announces U.S. Food and Drug Administration Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad